8-K: 180 Life Sciences Corp. Acquires iGaming Platform, Reports Positive CBD Study Results, and Strengthens Balance Sheet

180 Life Sciences Corp. has acquired an online gaming technology platform, reported positive results from a CBD pill study, and improved its financial position by settling legacy liabilities.

Summary

• 180 Life Sciences Corp. has acquired a comprehensive iGaming technology platform, marking a strategic shift into the online gaming industry.
• The acquired platform includes blockchain casino operations back-end, blockchain to FIAT exchange technology, payment gateway APIs, player account management, loyalty systems, and an affiliate tracking system.
• The company issued 1 million shares of Series B Convertible Preferred Stock and warrants to purchase 3 million shares of common stock for the acquisition.
• 180 Life Sciences believes this acquisition will help them meet Nasdaq's minimum stockholder equity requirements for continued listing.
• The company also reported positive study results for its synthetic CBD analogs (SCAs) in pill form, showing faster absorption and improved bioavailability compared to liquid CBD.
• 180 Life Sciences has settled legacy debts and litigation matters, strengthening its balance sheet and removing a major overhang.
• The global online gaming sector is estimated to reach $97 billion in 2024 and is projected to grow to nearly $133 billion by 2029.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the acquisition of a new business, positive study results, and improved financial position. However, there are still risks and uncertainties associated with the company's future performance.

Positives

• The acquisition of the iGaming platform positions the company in a rapidly growing market.
• The Gaming Technology Platform offers a competitive edge with its seamless integration of blockchain and FIAT technologies.
• The positive study results for the CBD pill form suggest a more reliable and convenient option for patients.
• Settling legacy debts and litigation matters has improved the company's financial position and removed a major overhang.
• The company expects to meet Nasdaq continued listing requirements.

Negatives

• The company needs to acquire or develop a front-end customer interface for the iGaming platform to become fully operational.
• There is no guarantee that Nasdaq will agree that the company has regained compliance with the Equity Rule.
• The company is subject to delisting if it does not meet Nasdaq's requirements.

Risks

• The company may not be able to maintain the continued listing of its securities on The Nasdaq Stock Market.
• The company may not be able to build out a front end for the Gaming Technology Platform, or the costs and timing may be prohibitive.
• The company may not be able to generate revenue from the Gaming Technology Platform.
• The company needs significant additional funding, and the ability to raise funding is not guaranteed.
• The company's drug candidates may not be successful in clinical trials or obtain regulatory approvals.
• The company relies on third parties to conduct its clinical trials and manufacture its drug supplies.
• The company may face challenges to its patents or lawsuits alleging intellectual property violations.

Future Outlook

The company plans to rebrand and prepare to enter the global iGaming market, while also exploring opportunities to maximize the value of its biotechnology assets. They also plan to acquire or develop a front-end customer interface for the iGaming platform.

Management Comments

• We believe that this acquisition is a pivotal moment for the Company, said Blair Jordan, Interim CEO of 180.
• We believe this transaction not only satisfies Nasdaqs minimum stockholder equity requirements for continued listing, but also sets the stage for the Companys entry into the dynamic and fast-growing global iGaming industry.
• Our new Gaming Technology Platform offers a competitive edge with its seamless integration of blockchain and FIAT technologies, providing a unique solution in the marketplace.

Industry Context

The acquisition of the iGaming platform positions 180 Life Sciences in the rapidly growing online gaming market, which is estimated to reach $97 billion in 2024 and is projected to grow to nearly $133 billion by 2029. The company is also leveraging blockchain technology, which is becoming increasingly popular in the online gaming industry.

Comparison to Industry Standards

• The document mentions that the global online gaming sector is estimated to reach $97 billion in 2024 and is projected to grow to nearly $133 billion by 2029, indicating a large and growing market.
• The company's use of blockchain technology aligns with a growing trend in the online gaming industry, where transparency and security are becoming increasingly important.
• The company's CBD pill study results are compared to the FDA-approved liquid CBD drug, Epidiolex, suggesting a focus on developing products that meet or exceed industry standards.
• The company's settlement of legacy debts and litigation matters is a positive step towards improving its financial health, which is a key factor for success in any industry.

Legal Proceedings

• The company has successfully resolved certain longstanding legacy litigation.

Stakeholder Impact

• Shareholders may benefit from the company's entry into the iGaming market and the potential for increased revenue and value.
• Employees may have new opportunities in the iGaming sector.
• Customers may have access to new and innovative online gaming experiences.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company will undertake a rebranding and preparation phase to enter the global iGaming market.
• The company will acquire or develop a front-end customer interface for the iGaming platform.
• The company will continue to explore opportunities to maximize the value of its biotechnology assets.
• The company will file public disclosures demonstrating compliance with Nasdaq's stockholder equity requirements by October 15, 2024.

Key Dates

Keywords

iGaming, blockchain, online casino, CBD, synthetic CBD analogs, Nasdaq, stockholder equity, acquisition, biotechnology, pharmaceuticals